Case Studies

A Cambridge MA based therapeutics company asked Alacrita to provide feedback on the Phase III protocol design for its lead drug, specifically from an EU payer perspective. Alacrita’s expert European...

A leading research institute developing novel approaches for production of ophthalmic treatments asked Alacrita to conduct a market and competitive assessment of the current supplier base and...

A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with pre-clinical testing on pigs, as well as...

Challenge: A clinical stage biotech needed support with its regulatory due diligence activities for products in the respiratory field.

Alacrita was asked to assess the market opportunity for a novel anaemia therapy in order to facilitate discussions with potential partners. Alacrita conducted the assessment in two stages.

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company. Alacrita was commissioned to provide a reality...

10111A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care, and has mapped regulatory pathways that pertained to various classes of product. Having...

Drawing on expertise from its regulatory, gene therapy and manufacturing consultants, Alacrita conducted feasibility study and formulated a business case for a new GMP facility for production of...

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...